v3.26.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Financial Information

 

   2026   2025 
  

Three Months Ended

March 31,

 
   2026   2025 
Research and development  $      $    
Clinical   -    726,321 
Chemistry, manufacturing and controls and nonclinical   32,502    125,290 
Personnel related   351,222    429,530 
Total research and development  $383,724   $1,281,141 
Selling, general and administrative          
Compliance   1,011,796    719,644 
Marketing   206,333    - 
Personnel related   324,529    339,018 
Total selling, general and administrative   1,542,658    1,058,662 
Interest income   78,676    36,216 
Net loss  $(1,847,706)  $(2,303,587)